Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.

Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, Buyukberber S.

Ann Pharmacother. 2012 Oct;46(10):e27. doi: 10.1345/aph.1R160. Epub 2012 Oct 2.

PMID:
23032654
[PubMed - indexed for MEDLINE]
2.

Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.

Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T.

Clin Exp Nephrol. 2012 Apr;16(2):310-5. doi: 10.1007/s10157-011-0543-9. Epub 2011 Oct 1.

PMID:
21964704
[PubMed - indexed for MEDLINE]
3.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

PMID:
19558553
[PubMed - indexed for MEDLINE]
4.

Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.

Lee NR, Yhim HY, Yim CY, Kwak JY, Song EK.

Ann Pharmacother. 2011 Oct;45(10):e56. doi: 10.1345/aph.1Q038. Epub 2011 Sep 27.

PMID:
21954449
[PubMed - indexed for MEDLINE]
5.

Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.

Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.

PMID:
19745694
[PubMed - indexed for MEDLINE]
6.

Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.

Wong MK, Jarkowski A.

Pharmacotherapy. 2009 Apr;29(4):473-8. doi: 10.1592/phco.29.4.473. Review.

PMID:
19323623
[PubMed - indexed for MEDLINE]
7.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Hiles JJ, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661. Review.

PMID:
18192256
[PubMed - indexed for MEDLINE]
8.

Sunitinib: new drug. For some gastrointestinal stromal tumours.

[No authors listed]

Prescrire Int. 2007 Aug;16(90):138-41.

PMID:
17724833
[PubMed - indexed for MEDLINE]
9.

Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.

Jonkers IJ, van Buren M.

Clin Exp Nephrol. 2009 Aug;13(4):397-401. doi: 10.1007/s10157-009-0167-5. Epub 2009 Apr 21.

PMID:
19381758
[PubMed - indexed for MEDLINE]
10.

Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.

Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F.

Ann Oncol. 2008 Nov;19(11):1975. doi: 10.1093/annonc/mdn566. Epub 2008 Aug 22. No abstract available.

PMID:
18723549
[PubMed - indexed for MEDLINE]
Free Article
11.

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

Adams VR, Leggas M.

Clin Ther. 2007 Jul;29(7):1338-53. Review.

PMID:
17825686
[PubMed - indexed for MEDLINE]
12.

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J.

J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29. Review.

PMID:
20351323
[PubMed - indexed for MEDLINE]
Free Article
13.

Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.

Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R, Bukowski RM.

Cancer. 2008 Sep 15;113(6):1309-14. doi: 10.1002/cncr.23711.

PMID:
18618496
[PubMed - indexed for MEDLINE]
Free Article
14.

Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.

Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM.

Ann Oncol. 2010 Jan;21(1):184-5. doi: 10.1093/annonc/mdp472. Epub 2009 Nov 4. No abstract available.

PMID:
19889617
[PubMed - indexed for MEDLINE]
Free Article
15.

Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.

[No authors listed]

Prescrire Int. 2007 Aug;16(90):141-3.

PMID:
17724834
[PubMed - indexed for MEDLINE]
16.

Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.

Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, Schulz M.

Eur J Cancer. 2012 May;48(7):974-81. doi: 10.1016/j.ejca.2012.01.036. Epub 2012 Feb 28.

PMID:
22382202
[PubMed - indexed for MEDLINE]
17.

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.

J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. Epub 2008 Feb 12. No abstract available.

PMID:
18270341
[PubMed - indexed for MEDLINE]
Free Article
18.

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.

Grandinetti CA, Goldspiel BR.

Pharmacotherapy. 2007 Aug;27(8):1125-44. Review.

PMID:
17655513
[PubMed - indexed for MEDLINE]
19.

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.

J Urol. 2008 Jan;179(1):81-6; discussion 86. Epub 2007 Nov 12.

PMID:
17997441
[PubMed - indexed for MEDLINE]
20.

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

Ravaud A, Sire M.

Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201. No abstract available.

PMID:
19403939
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk